Laplace Interventional
Laplace: Innovating transcatheter tricuspid valve tech for enhanced life expectancy & quality.
Founded
2020Laplace: Innovating transcatheter tricuspid valve tech for enhanced life expectancy & quality.
Laplace Interventional, founded in Plymouth, MN, is a medical device company dedicated to developing innovative transcatheter tricuspid valve technology. The company's core mission is to enhance the life expectancy and quality of life for patients suffering from tricuspid regurgitation through minimally invasive procedures. Their primary product is a prosthetic valve designed to be delivered via a transcatheter approach, aiming to provide a less invasive alternative to traditional surgical methods.
Notable figures affiliated with Laplace Interventional include leading experts in cardiology and medical device innovation. The company has attracted significant interest from investors focused on advancing medical technologies. Key achievements include the development and ongoing refinement of their investigational device, which holds promise for transforming the treatment landscape for tricuspid regurgitation. Laplace Interventional's impact lies in its potential to offer a life-saving solution to a global patient population in need of advanced cardiac care.
Companies similar to Laplace Interventional include TriFlo Cardiovascular, Vdyne, InterValve and Opus Medical Therapies.
Laplace Interventional was founded in 2020.
Laplace Interventional's headquarters is located in Plymouth, MN, US.
Laplace Interventional's most recent funding round was for $12.9M (USD) in July 2023.
As of Jul 24, 2023, Laplace Interventional has raised a total of $20.8M (USD).
Laplace Interventional has 11 employees as of Feb 5, 2024.
InterValve
